U.S. reported the first outbreak of deadly H7N9 bird flu since 2017. The strain was reported on a poultry farm. The country continues to grapple with another bird flu strain. (Reuters)
The National Institutes of Health has cancelled funding for an ongoing 30 year nationwide landmark diabetes study. While researchers working on the landmark Diabetes Prevention Program have not yet received word as to why funding was cancelled, it has been reported that the decision was likely linked with the Trump administration’s cancellation of funds to Columbia University on grounds that it failed to address antisemitism on campus. (STAT News)
AstraZeneca will buy EsoBiotech for up to $1 billion. The deal aims to accelerate the pharma’s development of its cancer cell capabilities. (The Guardian)
All selected drugmakers agree to a second round of Medicare price negotiations. The list includes 15 drugs. (Endpoints News)
Novo Nordisk has been restored as a member of the UK Pharmaceutical Industry Association after a two-year suspension. It was restored after extensive audits of the company’s compliance procedures. The suspension ensued due to serious breaches of the Association of the British Pharmaceutical Industry Code of Practice. (Bloomberg Law)
Click here to see yesterday’s Five things for pharma marketers to know.
